1. Failure to respond to an ANDA complete response letter within the regulatory timeframe: guidance for industry Publication: Silver Spring, MD : Center for Drug Evaluation and Research, December 2022 Subject(s): Drug ApprovalDrugs, GenericGovernment RegulationUnited StatesUnited States. Food and Drug Administration
